Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
暂无分享，去创建一个
M. Kudo | S. Thongprasert | Yoon-Koo Kang | Y. Chao | R. Poon | A. Cheng | M. Ikeda | H. Pan | G. Han | S. Chan | H. Lim | W. Sukeepaisarnjaroen | B. Balsara | Cheng‐Chung Wu | K. Numata | Ho Yeong Lim | Yi Zhang | Yongyu Wang | T.S. Yang | Yong Zhang | A. Rodríguez